“True precision medicine through single-cell science.”
Our new and emerging analytical device produces rich data-sets by measuring hundreds of parameters from millions of individual cells. The resulting single-cell data holds the information needed for early disease detection, but it requires sophisticated and innovative computational approaches in order to extract the relevant information.
We are addressing this problem by developing artificial intelligence (AI) software for single-cell data analysis. The underlying best-in-class algorithms allow us to associate patterns in single-cell data with disease status.
We provide a powerful software solution (ScaiVision), unifying our AI technology for the global medical community and delivering it to those working in drug and diagnostic R&D.
To save lives by enabling precision medicine.
Dr. Peter Nestorov
Peter holds a PhD in Genetics from the University of Basel and a degree in Biochemistry from the University of Tübingen. He has been working in the emerging single-cell analysis market since 2015 and this gave him the inspiration to start Scailyte as co-founder and CEO in 2017.
Dr. Sarah Carl
Director Data Science
Sarah holds a PhD in Genetics from the University of Cambridge. She worked as a bioinformatician at the Friedrich Miescher Institute in Basel, Switzerland, for four years before joining Scailyte. Sarah joined Scailyte as a data scientist in 2018 and has been recently promoted to become Director of Data Science.
Dr. Andrius Serva
Director Corporate Development
Anna Dimitrova, ACCA
Director Finance & Operations
Anna is an ACCA graduate with a Master’s degree in Finance and Banking from Sofia University. Previously, she worked as a finance manager in a fast growing company, auditor in KPMG and business consultant in PwC. Anna joined the Scailyte team in 2018.
Join the Scailyte team
Are you ready to help us transform biomedical research and healthcare? Please send us your CV, and your letter of motivation to join Scailyte, in an email to: careers@scailyte.com
To achieve our mission, we are looking for smart, passionate and dedicated individuals who share our values, by dreaming big, to join our growing, energetic and fun team. We offer flexible working schedules and home-office options
Recent News
Recent News
Scailyte and Geninus announce a strategic partnership to develop a predictive assay for immune-checkpoint inhibitors in Non-Small Cell Lung Cancer patients
Artificial Intelligence (AI)-driven biomarker discovery innovator Scailyte and the global single-cel
Recent News
Scailyte and Volv Global announce strategic partnership to accelerate rare disease patient diagnosis
Two Artificial Intelligence (AI)-driven biomarker discovery companies Scailyte and Volv Global today
Recent News
Scailyte Quarterly Update, January 2021
Quarterly update on Scailyte's progress towards its mission to save millions of lives.
Recent News
ScaiVision® performs best-in-class at sample class prediction!
ScaiVision® v1.0.0 was released internally and benchmarked in a massive experiment, outperforming a
Recent News
Scailyte participates @ swissnex san francisco DEMO DAY!
Striving to internationalize and network, Scailyte participates and pitches at the swissnex Demo Day
Recent News
Scailyte Q3 2020 Update
Q3 2020 update on Scailyte's progress towards its mission to save millions of lives.
Recent News
ETH Industry E-Week 2020 features Scailyte with the headline: Using Artificial Intelligence to unlock the clinical potential of single-cell data.
As ETH- Spin-off Scailyte attends the 2020 Industry eWeek giving updates on the disease area focus,
Recent News
Scailyte and Geninus announce a strategic partnership to develop a predictive assay for immune-checkpoint inhibitors in Non-Small Cell Lung Cancer patients
Artificial Intelligence (AI)-driven biomarker discovery innovator Scailyte and the global single-cel
Recent News
Scailyte and Volv Global announce strategic partnership to accelerate rare disease patient diagnosis
Two Artificial Intelligence (AI)-driven biomarker discovery companies Scailyte and Volv Global today
Scailyte Quarterly Update, January 2021
Quarterly update on Scailyte's progress towards its mission to save millions of lives.
Recent News
ScaiVision® performs best-in-class at sample class prediction!
ScaiVision® v1.0.0 was released internally and benchmarked in a massive experiment, outperforming a
Scailyte participates @ swissnex san francisco DEMO DAY!
Striving to internationalize and network, Scailyte participates and pitches at the swissnex Demo Day
Recent News
Scailyte Q3 2020 Update
Q3 2020 update on Scailyte's progress towards its mission to save millions of lives.
ETH Industry E-Week 2020 features Scailyte with the headline: Using Artificial Intelligence to unlock the clinical potential of single-cell data.
As ETH- Spin-off Scailyte attends the 2020 Industry eWeek giving updates on the disease area focus,
Are you ready to help us transform biomedical research and healthcare? Please send us your CV, and your letter of motivation to join Scailyte, in an email to: careers@scailyte.com